Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 4/2017

21.08.2017 | Editorial

Future of Haemophilia Research in India

verfasst von: Kanjaksha Ghosh, Rinku Shukla

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Excerpt

Haemophilia represents a high-cost, low-volume disease [1]. Hence, in developing countries where 90% of haemophilia patients of the world live, it puts the government of the day in a conundrum, i.e. the limited resources of that country earmarked for health need to be distributed amongst management and prevention of various diseases which optimally helps the population of the country. Hence, there is a need for developing research protocols suitable for that country in an evidence-based manner. Haemophilia research in India is one of the examples of need-based research, often driven by patient organizations like the Haemophilia Federation of India [2]. In the last 30 years, a large number of research papers in haemophilia have contributed materially to our diagnostics, management and training of manpower in the country [3]. …
Literatur
1.
Zurück zum Zitat Ghosh K, Ghosh K (2016) Management of haemophilia in developing countries: challenges and options. Indian J Hematol Blood Transfus 32(3):347–355CrossRefPubMed Ghosh K, Ghosh K (2016) Management of haemophilia in developing countries: challenges and options. Indian J Hematol Blood Transfus 32(3):347–355CrossRefPubMed
2.
Zurück zum Zitat Ghosh K, Shetty S, Sahu D (2010) Haemophilia care in India: innovations and integrations by various chapters of Haemophilia Federation of India (HFI). Haemophilia 16(1):61–65CrossRefPubMed Ghosh K, Shetty S, Sahu D (2010) Haemophilia care in India: innovations and integrations by various chapters of Haemophilia Federation of India (HFI). Haemophilia 16(1):61–65CrossRefPubMed
3.
Zurück zum Zitat Ghosh K (2004) Management of haemophilia and its complications in developing countries. Clin Lab Haematol 26(4):243–251CrossRefPubMed Ghosh K (2004) Management of haemophilia and its complications in developing countries. Clin Lab Haematol 26(4):243–251CrossRefPubMed
4.
Zurück zum Zitat Ghosh K, Ghosh K, Shetty S (2012) Hemostasis research in India: past, present, and future. Clin Appl Thromb Hemost 18(2):128–133CrossRefPubMed Ghosh K, Ghosh K, Shetty S (2012) Hemostasis research in India: past, present, and future. Clin Appl Thromb Hemost 18(2):128–133CrossRefPubMed
5.
Zurück zum Zitat Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V et al (2016) A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med 374:2054–2064CrossRefPubMed Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V et al (2016) A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med 374:2054–2064CrossRefPubMed
6.
Zurück zum Zitat Shetty S, Shelar T, Mirgal D, Nawadkar V, Pinto P, Shabhag S et al (2014) Rare coagulation factor deficiencies: a countrywide screening data from India. Haemophilia 20(4):575–581CrossRefPubMed Shetty S, Shelar T, Mirgal D, Nawadkar V, Pinto P, Shabhag S et al (2014) Rare coagulation factor deficiencies: a countrywide screening data from India. Haemophilia 20(4):575–581CrossRefPubMed
7.
Zurück zum Zitat Shetty S, Ghosh K (2012) Cancers in patients with hemophilia: a retrospective study from the Italian Association of Hemophilia Centers: a rebuttal. J Thromb Haemost 10(6):1200–1201CrossRefPubMed Shetty S, Ghosh K (2012) Cancers in patients with hemophilia: a retrospective study from the Italian Association of Hemophilia Centers: a rebuttal. J Thromb Haemost 10(6):1200–1201CrossRefPubMed
8.
Zurück zum Zitat Shetty S, Sharma N, Ghosh K (2016) Epidemiology of hepatocellular carcinoma (HCC) in hemophilia. Crit Rev Oncol Hematol 99:129–133CrossRefPubMed Shetty S, Sharma N, Ghosh K (2016) Epidemiology of hepatocellular carcinoma (HCC) in hemophilia. Crit Rev Oncol Hematol 99:129–133CrossRefPubMed
9.
Zurück zum Zitat Sen D, Balakrishnan B, Gabriel N, Agrawal P, Roshini V, Samuel R et al (2013) Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy. Sci Rep 3:1832CrossRefPubMed Sen D, Balakrishnan B, Gabriel N, Agrawal P, Roshini V, Samuel R et al (2013) Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy. Sci Rep 3:1832CrossRefPubMed
10.
Zurück zum Zitat Shetty S, Vora S, Kulkarni B, Mota L, Vijapurkar M, Quadros L, Ghosh K (2007) Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. Br J Haematol 138(4):541–544CrossRefPubMed Shetty S, Vora S, Kulkarni B, Mota L, Vijapurkar M, Quadros L, Ghosh K (2007) Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. Br J Haematol 138(4):541–544CrossRefPubMed
11.
Zurück zum Zitat Sehgal A, Barros S, Ivanciu L, Cooley B, Qin J, Racie T et al (2015) An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 21(5):492–497CrossRefPubMed Sehgal A, Barros S, Ivanciu L, Cooley B, Qin J, Racie T et al (2015) An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 21(5):492–497CrossRefPubMed
12.
Zurück zum Zitat Nair PS, Shetty S, Ghosh K (2016) Factor VIII antigen, activity, and mutations in hemophilia A. Clin Appl Thromb Hemost 22(4):381–385CrossRefPubMed Nair PS, Shetty S, Ghosh K (2016) Factor VIII antigen, activity, and mutations in hemophilia A. Clin Appl Thromb Hemost 22(4):381–385CrossRefPubMed
13.
Zurück zum Zitat Shetty S, Ghosh K, Jijina F (2006) First-trimester prenatal diagnosis in haemophilia A and B families—10 years experience from a centre in India. Prenat Diagn 26(11):1015–1017CrossRefPubMed Shetty S, Ghosh K, Jijina F (2006) First-trimester prenatal diagnosis in haemophilia A and B families—10 years experience from a centre in India. Prenat Diagn 26(11):1015–1017CrossRefPubMed
14.
Zurück zum Zitat Ranjan R, Biswas A, Kannan M, Meena A, Deka D, Saxena R (2007) Prenatal diagnosis of haemophilia A by chorionic villus sampling and cordocentesis: all India Institute of Medical Science experience. Vox Sang 92(1):79–84CrossRefPubMed Ranjan R, Biswas A, Kannan M, Meena A, Deka D, Saxena R (2007) Prenatal diagnosis of haemophilia A by chorionic villus sampling and cordocentesis: all India Institute of Medical Science experience. Vox Sang 92(1):79–84CrossRefPubMed
15.
Zurück zum Zitat Verma SP, Dutta TK, Mahadevan S, Nalini P, Basu D, Biswal N et al (2016) A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia—a success story from a resource limited country. Haemophilia 22(3):342–348CrossRefPubMed Verma SP, Dutta TK, Mahadevan S, Nalini P, Basu D, Biswal N et al (2016) A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia—a success story from a resource limited country. Haemophilia 22(3):342–348CrossRefPubMed
16.
Zurück zum Zitat Kundu T, Shaikh A, Kutty A, Nalvade A, Kulkarni S, Kulkarni R, Ghosh K (2012) Homeopathic medicines substantially reduce the need for clotting factor concentrates in haemophilia patients: results of a blinded placebo controlled cross over trial. Homeopathy 101(1):38–43CrossRefPubMed Kundu T, Shaikh A, Kutty A, Nalvade A, Kulkarni S, Kulkarni R, Ghosh K (2012) Homeopathic medicines substantially reduce the need for clotting factor concentrates in haemophilia patients: results of a blinded placebo controlled cross over trial. Homeopathy 101(1):38–43CrossRefPubMed
17.
Zurück zum Zitat Yadav N, Kanjirakkuzhiyil S, Kumar S, Jain M, Halder A, Saxena R, Mukhopadhyay A (2009) The therapeutic effect of bone marrow-derived liver cells in the phenotypic correction of murine hemophilia A. Blood 114(20):4552–4561CrossRefPubMed Yadav N, Kanjirakkuzhiyil S, Kumar S, Jain M, Halder A, Saxena R, Mukhopadhyay A (2009) The therapeutic effect of bone marrow-derived liver cells in the phenotypic correction of murine hemophilia A. Blood 114(20):4552–4561CrossRefPubMed
18.
Zurück zum Zitat Ragni MV, Humar A, Stock PG, Blumberg EA, Eghtesad B, Fung JJ et al (2017) Hemophilia liver transplantation observational study. Liver Transpl 23(6):762–768CrossRefPubMed Ragni MV, Humar A, Stock PG, Blumberg EA, Eghtesad B, Fung JJ et al (2017) Hemophilia liver transplantation observational study. Liver Transpl 23(6):762–768CrossRefPubMed
Metadaten
Titel
Future of Haemophilia Research in India
verfasst von
Kanjaksha Ghosh
Rinku Shukla
Publikationsdatum
21.08.2017
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 4/2017
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-017-0862-4

Weitere Artikel der Ausgabe 4/2017

Indian Journal of Hematology and Blood Transfusion 4/2017 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.